How peptide drugs are developed
From mechanism and preclinical work to human trials and approval.
A peptide drug candidate usually begins with a mechanistic rationale — a receptor or pathway it is designed to affect. Early work happens in cells (in vitro) and animals (in vivo) to probe activity and safety.
Only a fraction of candidates advance to human trials, which proceed through phases that test safety and then efficacy in progressively larger groups. Regulatory approval requires evidence that benefits outweigh risks for a defined use.
Most compounds discussed online as 'research peptides' have not completed this path. That is the core distinction this site tracks: approved drugs versus research-use-only compounds.
Educational and research reference only. Not medical advice.